Sullivan Timothy Eugene's Form 4 filing
Apellis Pharmaceuticals, Inc.APLS · filed Jul 6, 2023
- Accession no.
- 0001127602-23-020394
- Filed
- Jul 6, 2023
- Trade date
- Jul 3, 2023
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $609.9K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sullivan Timothy EugeneCIK 0001707000 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 3, 2023 | Common Stock | MOption exerciseAcquired | +6,779 | $10.03 | +$67,993.37 | 84,492 | Direct | |
| Jul 3, 2023 | Common Stock | SSaleDisposed | −3,192 | $89.41F2 | −$285,396.72 | 81,300 | Direct | |
| Jul 3, 2023 | Common Stock | SSaleDisposed | −3,287 | $90.42F3 | −$297,210.54 | 78,013 | Direct | |
| Jul 3, 2023 | Common Stock | SSaleDisposed | −300 | $91.10F4 | −$27,330 | 77,713 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 3, 2023 | Common Stock | MOption exerciseDisposed | −6,779 | $0.00 | $0 | 282,061 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $88.960 - $89.890. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $89.980 - $90.940. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $91.075 - $91.110. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.